Cytokinetics (NASDAQ: CYTK) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Cytokinetics to similar companies based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, valuation and institutional ownership.
This table compares Cytokinetics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cytokinetics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Cytokinetics’ competitors have a beta of 5.99, indicating that their average stock price is 499% more volatile than the S&P 500.
Earnings & Valuation
This table compares Cytokinetics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cytokinetics||$106.41 million||$16.45 million||-5.06|
|Cytokinetics Competitors||$284.49 million||$33.78 million||82.78|
Cytokinetics’ competitors have higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
73.7% of Cytokinetics shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.2% of Cytokinetics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Cytokinetics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytokinetics presently has a consensus price target of $17.90, suggesting a potential upside of 113.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.23%. Given Cytokinetics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytokinetics is more favorable than its competitors.
Cytokinetics beats its competitors on 7 of the 12 factors compared.
Cytokinetics Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.